Regeneron Pharmaceuticals, Inc.
REGNRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Drugs in Pipeline
141
Phase 3 Programs
67
Upcoming Catalysts
36
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
37 upcoming, 4 past
How REGN's past catalysts played out
Dupixent
Dupilumab
Atopic Dermatitis
Pozelimab
CD55-deficient Protein-losing Enteropathy
Libtayo
Cemiplimab
Non-Small Cell Lung Cancer
Intravitreal Aflibercept Injection (IAI)
Neovascular Age-Related Macular Degeneration
Alirocumab
Homozygous Familial Hypercholesterolemia
Statin
Hypercholesterolemia
REGN5715
Allergic Conjunctivitis
REGN5714
Allergic Rhinitis
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Dupilumab
Atopic Dermatitis (AD)
Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)
aflibercept
Diabetic Macular Edema
Cemdisiran
Paroxysmal Nocturnal Hemoglobinuria
Rilonacept
Gout
cemiplimab
Advanced Cutaneous Squamous Cell Carcinoma
Fasinumab
Osteoarthritis of the Knee or Hip
Fianlimab
Melanoma
mibavademab
Generalized Lipodystrophy
Rilonacept 80 mg
Intercritical Gout
REGN7508
Venous Thromboembolism (VTE)
Intravitreal Aflibercept Injection 2mg
Neovascular Age-related Macular Degeneration
Sarilumab
COVID-19
REGN-2Cat
Allergic Conjunctivitis
REGN10933 + REGN10987
Healthy Participants
Intravitreal aflibercept injection [IAI]
Nonproliferative Diabetic Retinopathy
REGN5713
Allergic Rhinitis
Indomethacin
Acute Gout Flare
aflibercept 8 mg PFS
Diabetic Macular Edema (DME)
Investigator Choice (IC) Chemotherapy
Squamous Cell Carcinoma (SCC)
Suptavumab 30 mg/kg
Respiratory Syncytial Virus Infections
Elotuzumab
Relapsed Refractory Multiple Myeloma (RRMM)
Garetosmab
Fibrodysplasia Ossificans Progressiva
Evinacumab
Hypercholesterolemia
Linvoseltamab
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Naproxen
Osteoarthritis, Knee
Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)
VEGF Trap-Eye 2.0mg
Macular Edema Secondary to Central Retinal Vein Occlusion
ranibizumab
Macular Degeneration
REGN9933
Venous Thromboembolism
Oral corticosteroids (OCS)
Bullous Pemphigoid
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Diabetic Macular Edema
REGN1908
Allergic Conjunctivitis
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Macular Degeneration
Rivaroxaban
Peripheral Artery Disease (PAD)
REGN475
Sciatica
REGN2810
Non-small Cell Lung Cancer
Acetylsalicylic Acid (ASA)
Symptomatic Venous Thromboembolism (VTE)
2.0 mg intravitreal aflibercept
Diabetic Macular Edema
Fluorouracil
Colorectal Cancer Metastatic
Atorvastatin
Hypercholesterolemia
Folic acid
Rheumatoid Arthritis
2-mg Intravitreous Aflibercept Injection
Proliferative Diabetic Retinopathy
Eylea (Aflibercept, BAY86-5321)
Retinopathy of Prematurity (ROP)
Prompt aflibercept
Diabetic Macular Edema
Simvastatin
Hypercholesterolemia
Non-statin Lipid-Modifying Therapy
Hypercholesterolemia
Dupilumab Prefilled Syringe
Asthma Control
Prednisone/Prenisolone
Follicular Lymphoma (FL)
Alirocumab 150 MG/ML [Praluent]
Hemodialysis
VEGF Trap-Eye (BAY86-5321)
Diabetes Mellitus
Ramucirumab
Recurrent Lung Non-Small Cell Carcinoma
Deferred aflibercept
Diabetic Retinopathy
Etoposide Phosphate
B-cell Non Hodgkin Lymphoma
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Macular Edema
Enoxaparin
Venous Thromboembolism
Dupilumab (blinded)
Eosinophilic Gastritis
Vonsetamig
Chronic Kidney Disease (CKD)
Cemiplimab 350 MG Intravenous Solution
Clear Cell Renal Cell Carcinoma
REGN5093
NSCLC
ZIV-Aflibercept
Metastatic Uveal Melanoma
Intravitreal Aflibercept Injection
Diabetic Macular Edema
Fluticasone/Salmeterol combination therapy
Asthma
Ubamatamab
Ovarian Cancer
REGN5458
Multiple Myeloma
REGN5459
Relapsed Multiple Myeloma
ALN-ANG3
Diabetic Kidney Disease (DKD)
High-dose aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
REGN5678
Metastatic Castration-resistant Prostate Cancer
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Diffuse Large B-Cell Lymphoma
ALN-SOD
Amyotrophic Lateral Sclerosis (ALS)
REGN13335
Pulmonary Arterial Hypertension (PAH)
Encorafenib + Binimetinib
Melanoma BRAF V600E/K Mutated
Sirolimus
Cutaneous Squamous Cell Carcinoma
REGN15505
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
REGN7075
Advanced Solid Tumors
REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
REGN1908-1909
Cat Allergy
Marlotamig
Non-Small Cell Lung Cancer
Topical imiquimod
Cutaneous Basal Cell Carcinoma
Aspirin Challenge
Aspirin-exacerbated Respiratory Disease
REGN5668
Ovarian Cancer
Trevogrumab-Part A
Obesity
RP1
Cutaneous Squamous Cell Carcinoma
BNT116
Advanced Non-Small Cell Lung Cancer
Tocilizumab
Recurrent Ovarian Cancer
Motixafortide
Pancreatic Cancer
Platinum-based chemotherapy
Non-Small Cell Lung Cancer
Dupilumab 300Mg Solution for Injection
Pruritus
REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)
VEGF Trap Eye
Macular Degeneration
REGN10933+REGN10987 combination therapy
COVID-19
REGN910-3
Diabetic Macular Edema
ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
REGN7945+Linvoseltamab
Relapsed/Refractory Multiple Myeloma
Low-Dose REGN4461
Generalized Lipodystrophy
Cemiplimab Plus Gemcitabine
Pancreatic Ductal Adenocarcinoma (mPDAC)
Platinum Doublet
Non-small Cell Lung Cancer
REGN17372+Linvoseltamab
Relapsed Refractory Multiple Myeloma (RRMM)
ALN-CIDEB
Metabolic Dysfunction-Associated Steatotic Liver Disease
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Homozygous Familial Hypercholesterolemia
REGN10597
Melanoma
Platinum based chemotherapy
Carcinoma, Non-Small-Cell Lung
ALN-PNP
Healthy Volunteers
AR101
Peanut Allergy
FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
Aflibercept Injection
Diabetic Retinopathy
REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-CFB
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Olatorepatide
Overweight or Obesity
REGN2477
Fibrodysplasia Ossificans Progressiva
cemiplimab plus fianlimab
Colo-rectal Cancer
Cemiplimab-Rwlc
Non-small Cell Lung Cancer Stage III
Pexastimogene Devacirepvec (Pexa-Vec)
Renal Cell Carcinoma
Timothy Grass SCIT
Allergic Rhinitis
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Merkel Cell Carcinoma, Stage I
casirivimab+imdevimab
Healthy
Platinum Doublet Chemotherapy (PDC)
NSCLC
PB
Sepsis-Induced Hypotension
Pemetrexed (Alimta)
Pleural Mesotheliomas
REGN5381
Heart Failure
VV1
Melanoma
Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept
Thyroid Eye Disease
REGV131
Hemophilia B
REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
ISA101b
Cervical Cancer
Fixed Dose Combination (FDC) cemiplimab+fianlimab
Melanoma
REGN1033 (SAR391786)
Sarcopenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dupixent Dupilumab | Approved | Atopic Dermatitis | - | - |
Pozelimab | Phase 3 | CD55-deficient Protein-losing Enteropathy | - | - |
Libtayo Cemiplimab | Phase 3 | Non-Small Cell Lung Cancer | Fast Track | - |
Intravitreal Aflibercept Injection (IAI) | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Statin | Phase 3 | Hypercholesterolemia | - | - |
REGN5715 | Phase 3 | Allergic Conjunctivitis | - | - |
REGN5714 | Phase 3 | Allergic Rhinitis | - | - |
Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis | - | - |
LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
Dupilumab | Phase 3 | Atopic Dermatitis (AD) | - | - |
Odronextamab | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Rilonacept | Phase 3 | Gout | - | - |
cemiplimab | Phase 3 | Advanced Cutaneous Squamous Cell Carcinoma | - | - |
Fasinumab | Phase 3 | Osteoarthritis of the Knee or Hip | - | - |
Fianlimab | Phase 3 | Melanoma | - | - |
mibavademab | Phase 3 | Generalized Lipodystrophy | - | - |
Rilonacept 80 mg | Phase 3 | Intercritical Gout | - | - |
REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Intravitreal Aflibercept Injection 2mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Sarilumab | Phase 3 | COVID-19 | - | - |
REGN-2Cat | Phase 3 | Allergic Conjunctivitis | - | - |
REGN10933 + REGN10987 | Phase 3 | Healthy Participants | - | - |
Intravitreal aflibercept injection [IAI] | Phase 3 | Nonproliferative Diabetic Retinopathy | - | - |
REGN5713 | Phase 3 | Allergic Rhinitis | - | - |
Indomethacin | Phase 3 | Acute Gout Flare | - | - |
aflibercept 8 mg PFS | Phase 3 | Diabetic Macular Edema (DME) | - | - |
Investigator Choice (IC) Chemotherapy | Phase 3 | Squamous Cell Carcinoma (SCC) | - | - |
Suptavumab 30 mg/kg | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Elotuzumab | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Garetosmab | Phase 3 | Fibrodysplasia Ossificans Progressiva | - | - |
Evinacumab | Phase 3 | Hypercholesterolemia | - | - |
Linvoseltamab | Phase 3 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | - | - |
Naproxen | Phase 3 | Osteoarthritis, Knee | - | - |
Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
rilonacept 160 mg | Phase 3 | Familial Cold Autoinflammatory Syndrome (FCAS) | - | - |
VEGF Trap-Eye 2.0mg | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion | - | - |
ranibizumab | Phase 3 | Macular Degeneration | - | - |
REGN9933 | Phase 3 | Venous Thromboembolism | - | - |
Oral corticosteroids (OCS) | Phase 3 | Bullous Pemphigoid | - | - |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Diabetic Macular Edema | - | - |
REGN1908 | Phase 3 | Allergic Conjunctivitis | - | - |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Branch Retinal Vein Occlusion | - | - |
Aflibercept 8 mg | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Degeneration | - | - |
Rivaroxaban | Phase 3 | Peripheral Artery Disease (PAD) | - | - |
REGN475 | Phase 3 | Sciatica | - | - |
REGN2810 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Acetylsalicylic Acid (ASA) | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | - | - |
2.0 mg intravitreal aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Fluorouracil | Phase 3 | Colorectal Cancer Metastatic | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Folic acid | Phase 3 | Rheumatoid Arthritis | - | - |
2-mg Intravitreous Aflibercept Injection | Phase 3 | Proliferative Diabetic Retinopathy | - | - |
Eylea (Aflibercept, BAY86-5321) | Phase 3 | Retinopathy of Prematurity (ROP) | - | - |
Prompt aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Non-statin Lipid-Modifying Therapy | Phase 3 | Hypercholesterolemia | - | - |
Dupilumab Prefilled Syringe | Phase 3 | Asthma Control | - | - |
Prednisone/Prenisolone | Phase 3 | Follicular Lymphoma (FL) | - | - |
Alirocumab 150 MG/ML [Praluent] | Phase 3 | Hemodialysis | - | - |
VEGF Trap-Eye (BAY86-5321) | Phase 3 | Diabetes Mellitus | - | - |
Ramucirumab | Phase 3 | Recurrent Lung Non-Small Cell Carcinoma | - | - |
Deferred aflibercept | Phase 3 | Diabetic Retinopathy | - | - |
Etoposide Phosphate | Phase 3 | B-cell Non Hodgkin Lymphoma | - | - |
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Edema | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
Dupilumab (blinded) | Phase 2 | Eosinophilic Gastritis | - | - |
Vonsetamig | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
Cemiplimab 350 MG Intravenous Solution | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
REGN5093 | Phase 2 | NSCLC | - | - |
ZIV-Aflibercept | Phase 2 | Metastatic Uveal Melanoma | - | - |
Intravitreal Aflibercept Injection | Phase 2 | Diabetic Macular Edema | - | - |
Fluticasone/Salmeterol combination therapy | Phase 2 | Asthma | - | - |
Ubamatamab | Phase 2 | Ovarian Cancer | - | - |
REGN5458 | Phase 2 | Multiple Myeloma | OrphanFast TrackBreakthrough | - |
REGN5459 | Phase 2 | Relapsed Multiple Myeloma | - | - |
ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) | - | - |
High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Chimeric Antigen Receptor T-Cell Therapy | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | - | - |
ALN-SOD | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
REGN13335 | Phase 2 | Pulmonary Arterial Hypertension (PAH) | - | - |
Encorafenib + Binimetinib | Phase 2 | Melanoma BRAF V600E/K Mutated | - | - |
Sirolimus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
REGN15505 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
REGN7075 | Phase 2 | Advanced Solid Tumors | - | - |
REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment | - | - |
REGN1908-1909 | Phase 2 | Cat Allergy | - | - |
Marlotamig | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Topical imiquimod | Phase 2 | Cutaneous Basal Cell Carcinoma | - | - |
Aspirin Challenge | Phase 2 | Aspirin-exacerbated Respiratory Disease | - | - |
REGN5668 | Phase 2 | Ovarian Cancer | - | - |
Trevogrumab-Part A | Phase 2 | Obesity | - | - |
RP1 | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
Tocilizumab | Phase 2 | Recurrent Ovarian Cancer | - | - |
Motixafortide | Phase 2 | Pancreatic Cancer | - | - |
Platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Dupilumab 300Mg Solution for Injection | Phase 2 | Pruritus | - | - |
REGN7544 | Phase 2 | Postural Orthostatic Tachycardia Syndrome (POTS) | - | - |
VEGF Trap Eye | Phase 2 | Macular Degeneration | - | - |
REGN10933+REGN10987 combination therapy | Phase 2 | COVID-19 | - | - |
REGN910-3 | Phase 2 | Diabetic Macular Edema | - | - |
ALN-HSD | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - | - |
REGN7945+Linvoseltamab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Low-Dose REGN4461 | Phase 2 | Generalized Lipodystrophy | - | - |
Cemiplimab Plus Gemcitabine | Phase 2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | - | - |
Platinum Doublet | Phase 2 | Non-small Cell Lung Cancer | - | - |
REGN17372+Linvoseltamab | Phase 2 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
ALN-CIDEB | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - | - |
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
REGN10597 | Phase 2 | Melanoma | - | - |
Platinum based chemotherapy | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
ALN-PNP | Phase 2 | Healthy Volunteers | - | - |
AR101 | Phase 2 | Peanut Allergy | - | - |
FDC fianlimab+cemiplimab | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
Aflibercept Injection | Phase 2 | Diabetic Retinopathy | - | - |
REGN3918 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
ALN-CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
Olatorepatide | Phase 2 | Overweight or Obesity | - | - |
REGN2477 | Phase 2 | Fibrodysplasia Ossificans Progressiva | - | - |
cemiplimab plus fianlimab | Phase 2 | Colo-rectal Cancer | - | - |
Cemiplimab-Rwlc | Phase 2 | Non-small Cell Lung Cancer Stage III | - | - |
Pexastimogene Devacirepvec (Pexa-Vec) | Phase 2 | Renal Cell Carcinoma | - | - |
Timothy Grass SCIT | Phase 2 | Allergic Rhinitis | - | - |
Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles | Phase 2 | Merkel Cell Carcinoma, Stage I | - | - |
casirivimab+imdevimab | Phase 2 | Healthy | - | - |
Platinum Doublet Chemotherapy (PDC) | Phase 2 | NSCLC | - | - |
PB | Phase 2 | Sepsis-Induced Hypotension | - | - |
Pemetrexed (Alimta) | Phase 2 | Pleural Mesotheliomas | - | - |
REGN5381 | Phase 2 | Heart Failure | - | - |
VV1 | Phase 2 | Melanoma | - | - |
Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept | Phase 2 | Thyroid Eye Disease | - | - |
REGV131 | Phase 2 | Hemophilia B | - | - |
REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | - | - |
ISA101b | Phase 2 | Cervical Cancer | - | - |
Fixed Dose Combination (FDC) cemiplimab+fianlimab | Phase 2 | Melanoma | - | - |
REGN1033 (SAR391786) | Phase 2 | Sarcopenia | - | - |
fibrodysplasia ossificans progressiva
3 drugs in this indication
Atopic Dermatitis
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Multiple Myeloma
1 drug in this indication
ultra-rare 'stone man disease'
1 drug in this indication
Fibrodysplasia Ossificans Progressiva (FOP)
1 drug in this indication
ultra-rare musculoskeletal condition
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Regeneron Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 141 drug candidates in Regeneron Pharmaceuticals, Inc.'s (REGN) pipeline across Phase 3, Phase 2, Approved. Its lead program is Pozelimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Regeneron Pharmaceuticals, Inc.'s next FDA catalyst?→
Regeneron Pharmaceuticals, Inc.'s (REGN) next tracked catalyst is a Phase 2 expected August 24, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REGN biotech catalysts?→
Add REGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Regeneron Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.